Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Income from Continuing Operations for 16 consecutive years, with 141229000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 2775.18% to 141229000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 220520000.0 through Dec 2025, down 1065.79% year-over-year, with the annual reading at 220474000.0 for FY2025, 1066.53% down from the prior year.
  • Income from Continuing Operations hit 141229000.0 in Q4 2025 for Vanda Pharmaceuticals, down from 22590000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 9604000.0 in Q2 2021 to a low of 141229000.0 in Q4 2025.
  • Historically, Income from Continuing Operations has averaged 9882950.0 across 5 years, with a median of 1127000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: surged 1856.46% in 2021 and later crashed 3986.13% in 2024.
  • Year by year, Income from Continuing Operations stood at 7098000.0 in 2021, then fell by 2.96% to 6888000.0 in 2022, then crashed by 134.71% to 2391000.0 in 2023, then crashed by 105.44% to 4912000.0 in 2024, then plummeted by 2775.18% to 141229000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VNDA at 141229000.0 in Q4 2025, 22590000.0 in Q3 2025, and 27207000.0 in Q2 2025.